logo
  

Granite Construction To Buy Kenny Construction For $130 Mln Cash - Quick Facts

Granite Construction Inc. (GVA) has agreed to acquire Kenny Construction Co., a national contractor and construction manager specializing in the power, tunnel, water and civil markets, for $130 million. Pursuant to the deal, Granite would pay $130 million cash at closing in return for 100% of Kenny's outstanding shares. Granite said it would receive a tax "step up" in the assets of Kenny and its divisions may provide future tax benefits to Granite. These benefits imply an effective purchase price of 5.0x Kenny's projected 2012 EBITDA.

Granite would finance the transaction via. a combination of cash and available borrowings as per its existing revolving credit facility. The transaction has been closed in escrow and would become effective on December 31, 2012. One-time costs related to the Kenny acquisition are projected to be nearly $5 million and would be recorded in the fourth quarter 2012, the company added.

Including integration costs and the impact of intangible amortization, the transaction may be break-even to Granite's 2013 earnings per share; while excluding intangible asset amortization, the transaction would be immediately accretive. These projections are based on preliminary estimates of the allocation of purchase price intangible assets, whereas the final allocation would be determined after completion.

BofA Merrill Lynch is acting as financial advisor to Granite in connection with the transaction. FMI Corp. is acting as financial advisor to Kenny.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT